CITIUS ONCOLOGY INC
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTOR$0.52-5.9%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
Checking your notes…
| Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | |
| Balance, 30-Sep-22 | - | - | 67,500,000 | 6,750 | 41,693,250 | (5,432,599) | 36,267,401 |
| Stock-based compensation expense | - | - | - | - | 1,965,500 | - | 1,965,500 |
| Net loss | - | - | - | - | - | (12,697,241) | (12,697,241) |
| Balance, 30-Sep-23 | - | - | 67,500,000 | 6,750 | 43,658,750 | (18,129,840) | 25,535,660 |
| Capital contributions by parent | - | - | - | - | 37,008,905 | 37,008,905 | |
| Stock-based compensation expense | - | - | - | - | 7,498,817 | 7,498,817 | |
| Merger, net of transaction costs of $2,358,780 | - | - | 4,052,402 | 405 | (2,754,701) | (2,754,296) | |
| Net loss | (21,148,747) | (21,148,747) | |||||
| Balance, 30-Sep-24 | - | - | 71,552,402 | 7,155 | 85,411,771 | (39,278,587) | 46,140,339 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.